Online inquiry

IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ628MR)

This product GTTS-WQ628MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL9 gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000590.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3578
UniProt ID P15248
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ628MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13468MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ13955MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ12971MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ10592MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ13305MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ11642MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ763MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ5905MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CIM 331
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW